TY - JOUR
T1 - Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
AU - Klebanoff, Christopher A.
AU - Gattinoni, Luca
AU - Torabi-Parizi, Parizad
AU - Kerstann, Keith
AU - Cardones, Adela R.
AU - Finkelstein, Steven E.
AU - Palmer, Douglas C.
AU - Antony, Paul A.
AU - Hwang, Sam T.
AU - Rosenberg, Steven A.
AU - Waldmann, Thomas A.
AU - Restifo, Nicholas P.
PY - 2005/7/5
Y1 - 2005/7/5
N2 - Central memory CD8+ T cells (TCM) and effector memory CD8+ T cells (TEM) are found in humans and mice; however, their relative contributions to host immunity have only recently been examined in vivo. Further, the ability of TCM to treat an established tumor or infection has yet to be evaluated. To address the therapeutic potential of different tumor-reactive CD8+ T cell memory subsets, we used an established model for the in vitro generation of TCM and T EM by using IL-15 and IL-2, respectively. Adoptively transferred TCM exhibited a potent in vivo recall response when combined with tumor-antigen vaccination and exogenous IL-2, leading to the eradication of large established tumors. By contrast, TEM were far less effective on a per-cell basis. Microarray analysis revealed that the signature of highly in vivo effective antitumor T cells included the overexpression of genes responsible for trafficking to secondary lymphoid tissues. This gene expression profile correctly predicted the in vitro and in vivo lymphoid-homing attributes of tumor-reactive T cells. Furthermore, we found that homing to secondary lymphoid tissue is required for optimal tumor treatment. Our findings indicated that highly in vivo effective antitumor T cells were those that initially targeted secondary lymphoid tissue, rather than tumor sites, as had previously been postulated. Thus, tumor-reactive CD8+ T cell populations with the phenotypic and functional attributes of TCM may be superior to TEM/effector T cells for adoptive immunotherapies using concomitant tumor-antigen vaccination.
AB - Central memory CD8+ T cells (TCM) and effector memory CD8+ T cells (TEM) are found in humans and mice; however, their relative contributions to host immunity have only recently been examined in vivo. Further, the ability of TCM to treat an established tumor or infection has yet to be evaluated. To address the therapeutic potential of different tumor-reactive CD8+ T cell memory subsets, we used an established model for the in vitro generation of TCM and T EM by using IL-15 and IL-2, respectively. Adoptively transferred TCM exhibited a potent in vivo recall response when combined with tumor-antigen vaccination and exogenous IL-2, leading to the eradication of large established tumors. By contrast, TEM were far less effective on a per-cell basis. Microarray analysis revealed that the signature of highly in vivo effective antitumor T cells included the overexpression of genes responsible for trafficking to secondary lymphoid tissues. This gene expression profile correctly predicted the in vitro and in vivo lymphoid-homing attributes of tumor-reactive T cells. Furthermore, we found that homing to secondary lymphoid tissue is required for optimal tumor treatment. Our findings indicated that highly in vivo effective antitumor T cells were those that initially targeted secondary lymphoid tissue, rather than tumor sites, as had previously been postulated. Thus, tumor-reactive CD8+ T cell populations with the phenotypic and functional attributes of TCM may be superior to TEM/effector T cells for adoptive immunotherapies using concomitant tumor-antigen vaccination.
KW - Homing
KW - IL-15
KW - IL-2
KW - Immunotherapy
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=22144437688&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22144437688&partnerID=8YFLogxK
U2 - 10.1073/pnas.0503726102
DO - 10.1073/pnas.0503726102
M3 - Article
C2 - 15980149
AN - SCOPUS:22144437688
SN - 0027-8424
VL - 102
SP - 9571
EP - 9576
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 27
ER -